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Abstract
Engagement of the CD3/T cell receptor complex in systemic lupus erythematosus (SLE) T cells involves Syk rather
than the zeta-associated protein. Because Syk is being considered as a therapeutic target we asked whether Syk is
central to the multiple aberrantly modulated molecules in SLE T cells. Using a gene expression array, we
demonstrate that forced expression of Syk in normal T cells reproduces most of the aberrantly expressed molecules
whereas silencing of Syk in SLE T cells normalizes the expression of most abnormally expressed molecules. Protein
along with gene expression modulation for select molecules was confirmed. Specifically, levels of cytokine IL-21, cell
surface receptor CD44, and intracellular molecules PP2A and OAS2 increased following Syk overexpression in
normal T cells and decreased after Syk silencing in SLE T cells. Our results demonstrate that levels of Syk affect the
expression of a number of enzymes, cytokines and receptors that play a key role in the development of disease
pathogenesis in SLE and provide support for therapeutic targeting in SLE patients.
Citation: Grammatikos AP, Ghosh D, Devlin A, Kyttaris VC, Tsokos GC (2013) Spleen Tyrosine Kinase (Syk) Regulates Systemic Lupus Erythematosus
(SLE) T Cell Signaling. PLoS ONE 8(8): e74550. doi:10.1371/journal.pone.0074550
Editor: Stamatis-Nick Liossis, University of Patras Medical School, Greece
Received June 18, 2013; Accepted August 2, 2013; Published August 27, 2013
Copyright: © 2013 Grammatikos et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in whole by National Institutes of Health Grant RO1 AI42269. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: agramma1@bidmc.harvard.edu (AG); gtsokos@bidmc.harvard.edu (GT)
Introduction
Following recognition of an antigen on the surface of a major
histocompatibility complex (MHC) molecule, the T cell receptor
(TCR) initiates a number of signaling cascades that determine
cytokine production, cell survival, proliferation and
differentiation. The initial event, phosphorylation of
immunoreceptor tyrosine-based activation motifs (ITAMs) on
the cytosolic side of the TCR/CD3ζ chain complex, allows for
Zap70 (ζ-chain associated protein kinase) to be recruited to
CD3ζ. Zap70 becomes activated in this way and promotes the
recruitment and phosphorylation of other adaptor molecules
responsible of transmitting signals downstream.
Several studies have shown that TCR signaling is modified in
patients suffering from SLE [1,2]. Instead of transmitting signals
through TCR to CD3ζ and Zap70, an alternative pathway
comes into play involving FcRγ and spleen tyrosine kinase
(Syk) [3,4]. FcRγ is homologous in shape and function to CD3ζ
and takes its place in SLE T cells [5,6] and associates with
Syk. This alternative FcRγ/Syk duet is 100 times enzymatically
more potent than the canonical CD3ζ/Zap70. As a result,
following activation, SLE T cells exhibit higher intracytoplasmic
calcium flux and cytosolic protein tyrosine phosphorylation
[7,8].
To better understand the contribution of Syk in the aberrant
phenotype of SLE T cells we examined the effect of Syk on the
expression of molecules known to contribute to the
pathogenesis of SLE. A two-step approach was followed: (a)
Syk was overexpressed in healthy blood-donor T cells to
examine whether increased Syk expression creates SLE-like
phenotype; and (b) Syk was downregulated, using siRNA, in
SLE T cells to examine whether gene expression abnormalities
can be corrected. Our results show that Syk contributes
significantly to the abnormal expression of a number of
molecules associated with the immunopathogenesis of SLE.
Materials and Methods
Ethics statement and blood samples
This study was approved by the Institutional Review Board of
Beth Israel Deaconess Medical Center (BIDMC). Written
informed consent was obtained from all participating subjects
and all clinical investigation was conducted according to the
principles expressed in the Declaration of Helsinki. Blood
samples were obtained from 21 SLE patients attending the
Rheumatology Division of BIDMC and 14 healthy blood donors
from the Dana-Farber Cancer Institute. All participating patients
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fulfilled at least 4 out of 11 criteria for SLE as set forth by the
American College of Rheumatology [9]. Patient characteristics
are shown in Table 1. In each experiment samples from
different patient or healthy control blood donors were used. The
disease activity of the patients was determined using the
Systemic Lupus Erythematosus Activity Index (SLEDAI) [10].
Cells, reagents and antibodies
Total T cells were purified using the Rosette Sep T cell kit
(StemCell Technologies, Vancouver, Canada). Blood was
incubated with a purification mixture that contains antibodies
against CD14, CD16, CD19, CD56 and glyA and attaches non-
T cells to erythrocytes. Lymphocyte separation medium
(Cellgro, Manassas, VA) was subsequently used to separate
these complexes from T cells.
For flow cytometry the following antibodies were used: SYK-
PE from Santa Cruz Biotechnology (Santa Cruz, CA), CD3-PB
from Biolegend (San Diego, CA), CD44v3-APC from R&D
systems (Minneapolis, MN), CD44v6-FITC from Abcam
(Cambridge, MA) and IL-21-AlexaFluor647 from BD
Pharmingen (San Jose, CA).
For western blot the following antibodies were used: OAS2
from Proteintech (Chicago, IL), PP2A C subunit from Cell
Signaling (Boston, MA), β-actin from Sigma-Aldrich (St. Louis,
MO) and anti-rabbit HRP-conjugated secondary antibody from
Santa Cruz Biotechnology (Santa Cruz, CA).
Plasmid and siRNA transfections
Transient transfections of human T cells were carried out
using the Lonza Nucleofector system (Lonza, Cologne,
Germany). Briefly, 5 × 106 cells were resuspended in 100µl of
nucleofector solution, plasmid DNA (1µg/106 cells) was added,
and cells were transferred to cuvettes to be transfected using
the U-014 program. The PCMV6XL6 -SYK expression plasmid
from OriGene (Rockville, MD) was used.
For Syk silencing, T cells were transfected with 15nM of
either control siRNA or SYK-specific siRNA (Ambion, Grand
Island, NY). Pre-designed and validated siRNA was purchased
from Applied Biosystems (Grand Island, NY): SYK siRNA,
sense, CGCUCUUAAAGAUGAGUUATT, and antisense,
UAACUCAUCUUUAAGAGCGGG.
Following transfections, cells were rescued immediately in
prewarmed RPMI medium supplemented with 10% fetal bovine
serum and 1% penicillin and streptomycin in 24-well culture
plates.
RNA isolation and reverse transcription
Three million cells were lysed in RLT buffer and RNA was
extracted using Qiagen (Valencia, CA) RNeasy extraction kit. A
Table 1. Patient characteristics.
SLEDAI mean ±SEM: 2 ±1 (range: 0-9)
Sex 95% female
Race 50% black; 35% white; 10% mixed; 5% asian
Age mean ±SEM: 47 ±2 (range: 32-60)
DNase-I treatment step (Qiagen) was added to the standard
protocol to ensure exclusion of genomic DNA from the final
product. OD260/280 measurements were used as a measure of
quality of isolated RNA. T cell derived total RNA was reversely
transcribed into cDNA using Promega (Madison, WI) reverse
transcription system and a mixture of 1:10 oligo (dT)20 to
random hexamer primers. Reverse transcription was performed
in a conventional thermocycler.
Real-time PCR
Quantitative real time polymerase chain reaction (rtPCR)
was performed to measure gene expression levels using UPL
probes (Universal Probe Library) from Roche (Indianapolis, IN).
A reaction mixture of a total volume of 10µl was prepared in a
final concentration of 200nM for each primer, 100nM for the
probes, 1x LightCycler 480 Probes Master and cDNA. All
reagents were obtained from Roche (Indianapolis, IN) apart
from High Purity Salt Free (HPSF) primers obtained from
Eurofins MWG Operon (Huntsville, AL). Reactions were
prepared in 96 well plates and amplification was performed on
a Roche LightCycler 480 PCR instrument (Roche, Indianapolis,
IN). Detailed information on the primers and probes used is
given in Table S1.
Crossing points (Ct) were calculated using the second
derivative maximum method and expression levels were
normalized against two reference genes (CD3ε and GAPDH).
Ct values over 40 were excluded from the analysis.
Immunofluorescent staining
Half a million cells from each blood donor were stained ex
vivo for flow cytometry analysis. After harvesting, cells were
incubated at room temperature for 30 min with cell surface
fluorochrome-conjugated monoclonal antibodies. For
intracellular staining, cells were then resuspended in 100 µl of
Cytofix/Cytoperm solution (BD Biosciences, San Jose, CA) for
20 min at 4°C and washed twice in Perm/Wash solution (BD
Biosciences, San Jose, CA). After 30min incubation with
intracellular antibodies, cells were again washed and collected
by centrifugation at 400xg for 5 minutes.
Expression of cell surface and intracellular markers was
assessed on a BD Biosciences LSRII flow cytometer, and data
were gated and displayed in Flowing Software 2.5 (Turku
Centre for Biotechnology, Finland).
Western blotting
Cells were first pelleted and then lysed in
radioimmunoprecipitation assay (RIPA) buffer (Boston
Bioproducts, Ashland, MA). Lysates were then resolved on 4–
12% BisTris gels and transferred to polyvinylidene difluoride
(PVDF) membrane. Membranes were then blocked with 4%
nonfat milk in Tris-buffered saline with 0.05% Tween 20 (TBS-
T) for 1h and incubated with primary antibody at room
temperature for 1h. After washing three times with TBS-T
membranes were then incubated with horseradish peroxidase-
conjugated secondary antibody for 1h, washed three times and
developed with ECL detection reagents (GE Healthcare,
Piscataway, NJ). Bands were visualized in the Fujifilm
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PLOS ONE | www.plosone.org 2 August 2013 | Volume 8 | Issue 8 | e74550
LAS-4000 imager and densitometry performed in ImageJ
software (National Institutes of Health).
Analysis and statistical methods
Student’s t-test was used for statistical analysis. All plots
were constructed in Prism 5 (GraphPad, La Jolla, CA).
Results
a) Modulation of Syk expression in SLE-patient and
healthy blood-donor T cells
Although it is established that Syk is increased in SLE T cells
it has not been previously shown whether increased Syk
expression represents a primary or a secondary abnormality in
these cells. To determine this we first upregulated Syk
expression in healthy blood donor T cells using a SYK
expression vector. Following transfection with the expression
vector, cells were cultured for 72h and SYK messenger RNA
(mRNA) was measured using quantitative PCR. Syk
overexpression resulted in significant upregulation of Syk in all
experiments performed. Average expression levels more than
doubled in these cells in comparison to empty vector
transfected (Figure 1a). To examine whether this finding
translates into higher protein expression levels as well, Syk
was measured by flow cytometry. Syk was significantly
upregulated in those cells transfected with the SYK-expression
vector in comparison to those transfected with the empty vector
(Figure 1a).
To examine whether any of the abnormalities seen in SLE
patients are corrected following downregulation of SYK
expression we then used SLE patient T cells and silenced its
expression using a SYK-specific small interfering RNA (siRNA).
SYK mRNA levels were found to be significantly decreased in
SYK-siRNA transfected T cells in comparison to control siRNA
transfected ones (≥50%) (Figure 1b). Expression levels of Syk
at the protein level were also found to significantly decrease
following SYK silencing (Figure 1b). There was no correlation
between SLEDAI score and fold Syk change following SYK
silencing. These results demonstrate that SYK silencing was
successful in downregulating intracellular Syk expression at the
gene and protein levels.
b) SYK affects expression levels of genes associated
with SLE
To determine whether Syk regulates at the mRNA level the
production of cell molecules that are known to be aberrantly
expressed in SLE we used healthy blood donor T cells and
SYK expression was artificially induced using a SYK-
overexpression vector. A panel of 36 genes known to play an
important role in aberrant SLE T cell function was chosen to be
studied. We chose these genes because of their proven
association with SLE pathophysiology and our own
observations that this panel of genes can reliably differentiate
between SLE patients and controls ( [11] and unpublished
data). We indeed found that overexpression of SYK resulted in
upregulation of several of these molecules (Figure 2a). Most
notably, the expression of cytokine IL-21, cell surface molecule
CD44, and intracellular molecules PP2A and OAS2 were found
to substantially increase in cells overexpressing SYK (fold
increase in SYK overexpressing cells over controls: IL-21,
5.7±1.5; CD44, 4.2±2.2; PP2A, 1.5±1; OAS2, 1.5±0.3;
normalized against GAPDH and CD3ε).
Following the reverse approach, suppression of Syk
expression in SLE T cells resulted in a substantial decrease in
the expression of those genes (Figure 2b). Specifically,
Figure 1.  Induced Syk expression and Syk silencing in T cells.  a) T cells extracted from healthy blood-donors were transfected
with either a SYK (SYK) or an empty (EV) expression vector. Following 72h of incubation, cells were lysed, RNA extracted and SYK
expression levels measured in real-time PCR. SYK overexpression led to a significant increase in its mRNA levels in all four
experiments tested (left panel, normalized expression levels shown). To investigate whether this finding translates into protein
expression levels as well, whole T cells were used to be analyzed in flow cytometry. Syk protein was found to significantly increase
following SYK overexpression in all experiments tested (right panel, a representative plot is shown, plots gated on CD3+ T cells). b)
T cells extracted from SLE patients were transfected with either a SYK-specific (siRNA) or a control (control) siRNA and expression
levels of Syk were measured using real-time PCR and flow cytometry. The SYK silencing protocol led to a significant reduction in its
expression at both the mRNA (left panel) and protein levels (right panel).
doi: 10.1371/journal.pone.0074550.g001
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transcript levels of IL-21, PP2A, OAS2 and CD44 were all
found to decrease following siRNA-mediated SYK knockdown
(fold increase in SYK siRNA treated cells over controls: CD44,
-2.8±0.4; PP2A, -2.7±1.9; IL-21, -1.9±0.2; OAS2, -1.1±0.8,
normalized against GAPDH and CD3ε).
c) Forced SYK expression in healthy blood donor T
cells modulates expression levels of molecules
associated with the pathogenesis of SLE
To verify that changes seen at the mRNA level translate into
changes in protein expression, we measured the protein levels
of CD44, IL-21, PP2A and OAS2 following overexpression and
silencing of Syk. For CD44 in particular we measured splice
variants v3 and v6, as both are associated with SLE [12].
Overexpression of SYK in healthy blood donor T cells led to
a significant upregulation in expression of IL-21 cytokine and
CD44v6 receptor. A smaller increase in CD44v3 expression
was also seen although overall levels of this variant were found
to be quite low (Figure 3a, empty vector vs. SYK expressing
vector transfected T cells, mean positive cells±SEM: IL-21,
7.9±1 vs. 13±2.3, p=0.05; CD44v3, 2.1±0.3 vs. 2.6±0.4, p = ns;
CD44v6, 10.7±1.2 vs. 16±2.1, p=0.05).
To evaluate the effect of Syk forced expression on
cytoplasmic molecules PP2A and OAS2, cells were lysed in
RIPA buffer and subjected to Western blot. T cells transfected
Figure 2.  Intracellular levels of Syk affect the expression of genes associated with SLE immunopathogenesis.  a) Healthy
blood donor T cells were transfected with a SYK overexpression plasmid and the expression of an array of genes associated with
SLE immunopathogenesis was measured using real-time PCR. A number of genes known to be overexpressed in SLE patients
were found to be upregulated by SYK overexpression, like IL-21, CD44, OAS2 and PP2A (mean ±SEM fold expression changes
between overexpression and empty vector transfected cells in four different experiments are shown). b) SLE patient T cells were
transfected with either a SYK-specific siRNA or a control, non-silencing, siRNA. Silencing of SYK resulted in suppression of
expression of a number of genes known to be aberrantly upregulated in SLE. Notably, expression levels of IL-21, CD44, OAS2 and
PP2A were all found to decrease in SYK-knockdown T cells (mean ±SEM fold expression changes between silencing and control
transfected T cells in four different experiments are shown).
doi: 10.1371/journal.pone.0074550.g002
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with the SYK cDNA construct displayed a significant increase
in expression of both OAS2 and PP2A in comparison to empty
vector transfected (Figure 3b, empty vector vs. SYK expressing
vector transfected T cells, mean relative expression±SEM,
OAS2/actin ratio: 0.91±0.1 vs. 1.39±0.2, p=0.05; PP2A/actin
ratio: 0.49±0.1 vs. 1.23±0.3, p=0.05).
d) Silencing of SYK in SLE patient T cells corrects
disease-associated T cell abnormalities
We then measured protein expression of CD44v3, CD44v6,
IL-21, PP2A and OAS2 in SYK-siRNA treated SLE T cells.
Knockdown of SYK resulted in a significant decrease in
CD44v6 and IL-21 expression. Again, the decrease in CD44v3
expression was found to be smaller and overall expression
levels of this molecule quite low (Figure 4a, control vs. SYK
siRNA transfected T cells, mean positive cells±SEM: IL-21,
18.6±2.4 vs. 11.4±1.6, p=0.03; CD44v3, 2.9±0.3 vs. 1.8±0.2, p
= ns; CD44v6, 11.7±0.7 vs. 7.6±1.2, p=0.05).
T cells in which SYK had been silenced also displayed
decreased expression of OAS2 and PP2A in comparison to
control siRNA treated (Figure 4b, control vs. SYK siRNA
transfected T cells, mean relative expression±SEM, OAS2/
actin ratio: 1.47±0.2 vs. 1.13±0.1, p=0.03; PP2A/actin ratio:
1.26±0.3 vs. 0.78±0.2, p=0.05).
Figure 3.  Induced Syk expression upregulates expression levels of SLE-associated molecules in healthy blood donor T
cells.  a) SYK was overexpressed in healthy blood donor T cells using a transient nucleofection protocol and expression levels of
IL-21, CD44v3 and CD44v6 measured in flow cytometry. SYK overexpression resulted in the upregulation of the expression of all
these molecules at the protein level. Changes in expression of variant v6 of CD44 molecule seemed to account for most of the
changes seen at the mRNA level (bars show the mean ±SEM of SYK (SYK) vs. empty vector (EV) transfected T cells in ≥7
experiments). b) Following the same transfection protocol cells were lysed in RIPA buffer and subjected to western blot using
antibodies against PP2a, OAS2 and β-actin. Protein expression levels of both OAS2 and PP2a increased significantly following SYK
induced expression. Following measurement of band intensity the ratio of PP2a or OAS2 to β-actin was calculated in each
experiment (a representative experiment and cumulative data (mean ± SEM) from 10 experiments are shown).
doi: 10.1371/journal.pone.0074550.g003
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Discussion
SLE T cells express high levels of Syk and preferentially
transmit signals through FcRγ/Syk instead of the canonical
CD3ζ/ Zap70 pathway. This rewiring of the TCR signaling
complex is associated with profound transcriptional
dysregulation of several key molecules in SLE T cells [13].
Specifically, SLE T cells display upon activation increased
calcium flux, tyrosine phosphorylation and actin polymerization
[14].
We have shown previously that Syk expression is controlled
by the transcription factors c-Jun and Ets-2 and is
transcriptionally upregulated in SLE T cells [15] primarily due to
activated c-Jun. Syk inhibition using siRNA [15] or a small
molecule R406/R788 [3] resulted in decrease in the calcium
flux following SLE T cell activation, but had no effect on normal
T cells. Moreover, Syk inhibition decreased the rapid actin
polymerization of SLE T cells proving the importance of Syk in
SLE T cell activation. The global importance of Syk in SLE was
also shown in lupus prone mice, where treatment with R788
resulted in prevention of nephritis and dermatitis [16].
Given these findings we asked whether upregulation of Syk
in normal T cells can re-create the phenotype of SLE T cells;
and vice versa, whether downregulation of Syk can normalize
the expression of key signaling molecules in SLE T cells. We
chose to examine the expression of 39 signaling molecules that
have been linked to SLE T cell phenotype. Of those molecules,
four were most profoundly and consistently affected by Syk
overexpression and downregulation (Figure 5). Specifically,
overexpression of Syk resulted in upregulation of IL21, CD44,
Figure 4.  Silencing of SYK results in the suppression of aberrantly expressed molecules in SLE.  a) SLE patient T cells were
transfected with 15nM of either control or SYK-specific siRNA. Seventy-two hours following transfection cells were harvested and
stained with antibodies against IL-21, CD44v3 and CD44v6. Silencing of SYK resulted in the suppression of expression of all the
above molecules, particularly IL-21 and CD44v6. Bars show the mean ±SEM of control (control) vs. SYK-siRNA (siRNA) transfected
T cells in ≥7 experiments and a representative experiment is shown. b) Protein expression levels of OAS2 and PP2a measured in
western blot were found to decrease following silencing of SYK. Mean ±SEM of densitometry analyses of SYK-specific (siRNA) vs.
control (control) siRNA transfected cells in ≥6 experiments are plotted. A representative experiment and cumulative data are shown.
doi: 10.1371/journal.pone.0074550.g004
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PP2A and OAS2. Silencing of SYK, on the other hand, resulted
in downregulation of these molecules. Findings were consistent
at both the mRNA and protein levels for all molecules tested.
Out of the two CD44 receptor molecule variants most highly
associated with SLE (v3 and v6) [12] v6 was found to be
primarily affected by changes in Syk expression levels.
A number of previous studies have shown the importance of
the above molecules in SLE. IL-21, has been found to play an
important role in T cell-dependent B cell differentiation into
plasma cells and the production of antibodies in SLE [17].
Hence Syk overexpressing SLE T cells can provide increased
help to B cells to produce pathogenic autoantibodies, a key
feature of the disease.
Expression of CD44, a cell-surface glycoprotein involved in
cell-cell interactions and cell adhesion is increased in SLE T
cells, allowing for increased adhesion and migration [18]. CD44
splice variants v3 and v6 in particular, are upregulated in SLE T
cells and their expression correlates with disease activity [12].
T cells in kidneys of SLE patients have been found to express
CD44 suggesting that these molecules may allow T cells to
migrate abnormally into kidneys in them [19]. Therefore Syk not
only controls actin polymerization upon SLE T cell activation,
but also by enhancing CD44 expression may lead to faster
adhesion and migration of T cells to tissues. Although both v3
and v6 variants are associated with SLE, we found that mainly
variant v6 is regulated by Syk. This finding may demonstrate a
variable role of Syk in the expression of these two splice
variants and points towards an important role for CD44v6 in the
pathogenesis of SLE.
PP2A (protein phosphatase 2), a serine/threonine
phosphatase that regulates a number of cellular processes,
plays an important role in SLE. SLE T cells express abnormally
high levels of PP2A, which leads to decreased expression of
interleukin-2 upon T cell activation [20]. As IL-2 is important for
Treg function, increased expression of PP2A may be in part
responsible for defective Treg function in SLE [21]. PP2A also
regulates the expression of CD3ζ and FcRγ, leading to TCR
rewiring [22] and further enhancing Syk recruitment to the TCR/
FcRγ complex. Moreover, PP2A-transgenic mice display
increased expression of IL-17 and increased susceptibility to
immune-mediated glomerulonephritis [23]. Therefore, Syk by
controlling at least in part the expression of PP2A, may
regulate the composition of TCR and tilt the balance of T cell
activation towards the pro-inflammatory Th17.
Finally, OAS2 (2'-5'-oligoadenylate synthetase) is an
interferon-induced molecule that is involved in the innate
immune response towards viral infection. OAS2 activates latent
RNase L which is involved in the degradation of viral RNA.
Along with several other interferon-inducible molecules, OAS2
has been found to be significantly upregulated in SLE [24].
These molecules represent the, so-called, ‘interferon-signature’
in SLE and are thought to be the result of high levels of type I
Inteferons (IFNs) in these patients. Type I IFNs play an
important role in the promotion of inflammatory responses; they
prevent activated T-cell death and contribute to the generation
of effector cells during viral infections [25]. They have also
been found to play a role in the process of CD8 T cell-
dependent generation of autoantigens [26].
Exactly how Syk affects the expression of these molecules
remains to be determined. Previous studies suggest some
possible links: Syk has been found to associate with adaptor
molecules Vav1, phospholipase Cγ1 (PLCγ1) [27,28] and
extracellular signal-regulated kinase (ERK) [29] in the process
of regulating the production of cytokines and other molecules.
Vav1 is a molecule known to activate NF-κB and, a member of
the NF-κB family, c-Rel, has been found to activate
transcription of IL-21 in T cells [30]. Finally, p38, a member of
the mitogen-activated protein kinase (MAPK) pathway (which
includes ERK) has been found to be involved in the expression
of CD44 in monocytes [31].
Figure 5.  Schematic representation of the proposed role of Syk in SLE.  Syk promotes the upregulation of a number of
cytokines, receptors and enzymes that play a key role in SLE immunopathogenesis. It affects expression levels of CD44, primarily
variant v6, involved in T cell migration; IL-21, involved in antibody production; OAS2, involved in type-I interferon responses; and
PP2A, involved in the regulation of IL-2 production.
doi: 10.1371/journal.pone.0074550.g005
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In this study, we focused on determining the effect of Syk on
resting T cells as we have previously shown the effect of Syk
overexpression/knockdown on the activation of T cells [15].
Therefore, the effect of Syk on the expression of molecules that
are produced by T cells upon activation (such as IL-2 or CD40
ligand) cannot be fully assessed.
In conclusion, our data show that overexpression of Syk in
healthy T cells recapitulates at least part of the SLE T cell
phenotype. Syk overexpressing T cells may provide more help
to B cells through IL21, have enhanced migration to tissues by
upregulating CD44 and produce proinflammatory rather than
counterinflammatory cytokines. Inhibiting Syk in SLE T cells
leads to the opposite effect, further underscoring Syk’s
potential as a therapeutic target in SLE.
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